Groupe d'etude et de travail sur les leucemies aigues promyelocytaires Report issue

Academic/Hospital Phase 3

Organization Overview

First Clinical Trial
1993
NCT00599937
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2000

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (2)

cytarabine (cytosar-u) (1 trial)

tretinoin (Retin-A) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Leukemia (Phase 3)

Leukemia, Promyelocytic, Acute (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 2